GLOBAL INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026
KEY FINDINGS
A global rise in infertility and increasing awareness about its effective treatments, combined with the emergence of medical tourism in fertility treatments are propelling the global infertility testing and treatment market. By the end of the forecast period of 2018 – 2026, the market is predicted to evolve at 6.39% CAGR.
MARKET INSIGHTS
The global infertility testing and treatment market is segmented on the basis of male infertility, female infertility and end-users. Both the male and female infertility markets are further sub-segmented into testing and treatment. Increasing number of couples are opting for IVF techniques, and as a result, the female infertility treatment segment is dominating the market. The end-users for this market are sub-segmented into hospitals and research laboratories, fertility and surgical centers, and cryobanks.
REGIONAL INSIGHTS
Asia-Pacific, Europe, North America and rest of the world are the markets focused for the global infertility testing and treatment market. The European market is expected to capture the highest market share by the end of the estimated period. The region has a presence of a number of IVF clinics that provide treatments at reasonable costs. The APAC market is also forecasted to exhibit a significant growth over the forecast period, driven by a low birth rate and favourable government initiatives in countries like Taiwan, South Korea, Singapore and Japan.
COMPETITIVE INSIGHTS
Major companies dealing in the infertility testing and treatment market include Endo Pharmaceuticals, Andrology Solutions, Progyny, Genea, Ferring Pharmaceuticals, Halotech DNA, Merck, Irvine Scientific, Origio, Vitrolife Ab, Ovascience, Thermo Fisher Scientific Inc, Quest Diagnostic, The Cooper Companies, Inc, Esco Micro Pte. Ltd, Alere, Elucigene, Celmatrix, Claritas Genomics, Veritas Genetics, Roche, Agilent, LabCorp, Integrated Genetics, Centogene, Phosphorus Diagnostics, Natera Inc, and Illumina Inc.
A global rise in infertility and increasing awareness about its effective treatments, combined with the emergence of medical tourism in fertility treatments are propelling the global infertility testing and treatment market. By the end of the forecast period of 2018 – 2026, the market is predicted to evolve at 6.39% CAGR.
MARKET INSIGHTS
The global infertility testing and treatment market is segmented on the basis of male infertility, female infertility and end-users. Both the male and female infertility markets are further sub-segmented into testing and treatment. Increasing number of couples are opting for IVF techniques, and as a result, the female infertility treatment segment is dominating the market. The end-users for this market are sub-segmented into hospitals and research laboratories, fertility and surgical centers, and cryobanks.
REGIONAL INSIGHTS
Asia-Pacific, Europe, North America and rest of the world are the markets focused for the global infertility testing and treatment market. The European market is expected to capture the highest market share by the end of the estimated period. The region has a presence of a number of IVF clinics that provide treatments at reasonable costs. The APAC market is also forecasted to exhibit a significant growth over the forecast period, driven by a low birth rate and favourable government initiatives in countries like Taiwan, South Korea, Singapore and Japan.
COMPETITIVE INSIGHTS
Major companies dealing in the infertility testing and treatment market include Endo Pharmaceuticals, Andrology Solutions, Progyny, Genea, Ferring Pharmaceuticals, Halotech DNA, Merck, Irvine Scientific, Origio, Vitrolife Ab, Ovascience, Thermo Fisher Scientific Inc, Quest Diagnostic, The Cooper Companies, Inc, Esco Micro Pte. Ltd, Alere, Elucigene, Celmatrix, Claritas Genomics, Veritas Genetics, Roche, Agilent, LabCorp, Integrated Genetics, Centogene, Phosphorus Diagnostics, Natera Inc, and Illumina Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE IS THE LARGEST MARKET
3.2.2. ASIA PACIFIC IS THE FASTEST GROWING REGION IN THE INFERTILITY MARKET
3.2.3. IVF DOMINATES THE FEMALE TREATMENT MARKET
3.2.4. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. MARKET DRIVERS AND IMPACT
4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED THE FERTILITY TREATMENT
4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
4.2.6. HEALTHIER DONOR EGGS
4.2.7. INTRODUCTION OF NEW TESTING DEVICES
4.3. RESTRAINTS AND IMPACT
4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED
4.3.2. COUNTRY-WISE REGULATORY ISSUES
4.4. MARKET OPPORTUNITIES
4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
4.5. MARKET CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. PERILS OF MULTIPLE PREGNANCIES
4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO INFERTILITY TREATMENTS
4.5.3.1. DIET AND SUPPLEMENTS
4.5.3.2. ACUPUNCTURE
4.5.3.3. THERAPY
4.5.3.4. QIGONG
5. INFERTILITY CAUSES
5.1. CAUSES OF MALE INFERTILITY
5.1.1. ABNORMALITY IN THE SPERM
5.1.2. ENVIRONMENTAL FACTORS
5.1.3. POOR HEALTH AND LIFESTYLE
5.2. CAUSES OF FEMALE INFERTILITY
5.2.1. OVULATION DISORDERS
5.2.2. DAMAGE TO FALLOPIAN TUBES
5.3. MORAL QUESTIONS
6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
6.1. MARKET BY MALE INFERTILITY TESTING
6.1.1. DNA FRAGMENTATION
6.1.2. OXIDATIVE STRESS ANALYSIS
6.1.3. SPERM PENETRATION ASSAY
6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
6.1.5. SPERM AGGLUTINATION
6.1.6. MICROSCOPIC EXAMINATION
6.1.7. OTHERS
6.2. MARKET BY MALE INFERTILITY TREATMENT
6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)
6.2.2. SPERM RETRIEVAL TREATMENT
6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
6.2.5. VARICOCELE REPAIRS
6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
6.2.7. INTRAUTERINE INSEMINATION (IUI)
6.2.8. IN VITRO FERTILIZATION (IVF)
6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
7.1. MARKET BY FEMALE INFERTILITY TESTING
7.1.1. OVULATION TESTING
7.1.2. HYSTEROSALPINGOGRAPHY
7.1.3. LAPAROSCOPY
7.1.4. TRANSVAGINAL ULTRASOUND
7.1.5. OVARIAN RESERVE TESTING
7.1.6. HORMONAL LEVEL TESTING
7.1.7. OTHERS (GENETIC TESTING)
7.2. MARKET BY FEMALE INFERTILITY TREATMENT
7.2.1. IN VITRO FERTILIZATION
7.2.2. INTRAUTERINE INSEMINATION (IUI)
7.2.3. DRUG AND HORMONE THERAPIES
8. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
8.1. FERTILITY AND SURGICAL CENTERS
8.2. HOSPITALS AND RESEARCH LABORATORIES
8.3. CRYOBANKS
9. KEY ANALYTICS
9.1. PORTER’S 5 FORCE MODEL
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCTS
9.1.3. BARGAINING POWER OF BUYERS
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. VALUE CHAIN ANALYSIS
9.2.1. RAW MATERIAL PROCUREMENT
9.2.2. MANUFACTURING
9.2.3. SUPPLY LOGISTICS
9.2.4. DISTRIBUTION CHANNELS
9.2.5. END USERS
9.3. KEY BUYING CRITERIA
9.3.1. TREATMENT OPTIONS
9.3.2. QUALITY OF MEDICAL PROCEDURES
9.3.3. PRICE OF TREATMENTS
9.3.4. SHIFT TOWARDS MEDICAL TOURISM
9.3.5. REIMBURSEMENT
9.4. REGULATORY FRAMEWORK
9.5. KEY TRENDS
9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
9.5.4. REGULATORY ENVIRONMENT- KEY MARKET ENABLER
9.5.5. MORE COUPLES OPTING FOR SURROGACY
9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
9.6. VENDOR LANDSCAPE
9.7. OPPORTUNITY MATRIX
10. KEY ANALYTICS – TESTING MARKET
10.1. PORTER’S 5 FORCE ANALYSIS
10.1.1. THREAT OF NEW ENTRANTS
10.1.2. THREAT OF SUBSTITUTE PRODUCTS
10.1.3. BARGAINING POWER OF BUYERS
10.1.4. BARGAINING POWER OF SUPPLIERS
10.1.5. INTENSITY OF COMPETITIVE RIVALRY
10.2. KEY BUYING CRITERIA
10.3. VENDOR LANDSCAPE
10.4. OPPORTUNITY MATRIX
11. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET REGIONAL ANALYSIS 2018-2026 ($ MILLION)
11.1. NORTH AMERICA
11.1.1. US
11.1.2. CANADA
11.2. ASIA PACIFIC
11.2.1. CHINA
11.2.2. INDIA
11.2.3. JAPAN
11.2.4. SOUTH KOREA
11.2.5. REST OF ASIA-PACIFIC
11.3. EUROPE
11.3.1. UK
11.3.2. GERMANY
11.3.3. FRANCE
11.3.4. NORDICS
11.3.5. RUSSIA
11.4. REST OF THE WORLD
12. COMPETITIVE ANALYSIS
12.1. ANDROLOGY SOLUTIONS
12.1.1. OVERVIEW
12.1.2. PRODUCT PORTFOLIO
12.1.3. SCOT ANALYSIS
12.2. ENDO PHARMACEUTICALS
12.2.1. OVERVIEW
12.2.2. PRODUCT PORTFOLIO
12.2.3. STRATEGIC MOVES
12.2.4. SCOT ANALYSIS
12.3. PROGYNY
12.3.1. OVERVIEW
12.3.2. PRODUCT PORTFOLIO
12.3.3. STRATEGIC MOVES
12.3.4. SCOT ANALYSIS
12.4. FERRING PHARMACEUTICALS
12.4.1. OVERVIEW
12.4.2. PRODUCT PORTFOLIO
12.4.3. STRATEGIC MOVES
12.4.4. SCOT ANALYSIS
12.5. GENEA
12.5.1. OVERVIEW
12.5.2. PRODUCT PORTFOLIO
12.5.3. STRATEGIC MOVES
12.5.4. SCOT ANALYSIS
12.6. HALOTECH DNA
12.6.1. OVERVIEW
12.6.2. PRODUCT PORTFOLIO
12.6.3. STRATEGIC MOVES
12.6.4. SCOT ANALYSIS
12.7. IRVINE SCIENTIFIC
12.7.1. OVERVIEW
12.7.2. PRODUCT PORTFOLIO
12.7.3. STRATEGIC MOVES
12.7.4. SCOT ANALYSIS
12.8. MERCK
12.8.1. OVERVIEW
12.8.2. PRODUCT PORTFOLIO
12.8.3. STRATEGIC MOVES
12.8.4. SCOT ANALYSIS
12.9. ORIGIO
12.9.1. OVERVIEW
12.9.2. PRODUCT PORTFOLIO
12.9.3. STRATEGIC MOVES
12.9.4. SCOT ANALYSIS
12.10. OVASCIENCE
12.10.1. OVERVIEW
12.10.2. PRODUCT PORTFOLIO
12.10.3. STRATEGIC MOVES
12.10.4. SCOT ANALYSIS
12.11. VITROLIFE AB
12.11.1. OVERVIEW
12.11.2. PRODUCT PORTFOLIO
12.11.3. STRATEGIC MOVES
12.11.4. SCOT ANALYSIS
12.12. THERMO FISHER SCIENTIFIC INC
12.12.1. OVERVIEW
12.12.2. PRODUCT PORTFOLIO
12.12.3. STRATEGIC MOVES
12.12.4. SCOT ANALYSIS
12.13. THE COOPER COMPANIES, INC
12.13.1. OVERVIEW
12.13.2. PRODUCT PORTFOLIO
12.13.3. STRATEGIC MOVES
12.13.4. SCOT ANALYSIS
12.14. QUEST DIAGNOSTIC
12.14.1. OVERVIEW
12.14.2. PRODUCT PORTFOLIO
12.14.3. SCOT ANALYSIS
12.14.4. STRATEGIC MOVES
12.15. ESCO MICRO PTE. LTD.
12.15.1. OVERVIEW
12.15.2. PRODUCT PORTFOLIO
12.15.3. STRATEGIC MOVES
12.15.4. SCOT ANALYSIS
12.16. ELUCIGENE
12.16.1. OVERVIEW
12.16.2. PRODUCT PORTFOLIO
12.16.3. SCOT ANALYSIS
12.16.4. STRATEGIC INITIATIVE
12.17. ALERE
12.17.1. OVERVIEW
12.17.2. PRODUCT PORTFOLIO
12.17.3. SCOT ANALYSIS
12.17.4. STRATEGIC INITIATIVE
12.18. CELMATRIX
12.18.1. OVERVIEW
12.18.2. PRODUCT PORTFOLIO
12.18.3. SCOT ANALYSIS
12.18.4. STRATEGIC INITIATIVE
12.19. VERITAS GENETICS
12.19.1. OVERVIEW
12.19.2. PRODUCT PORTFOLIO
12.19.3. SCOT ANALYSIS
12.19.4. STRATEGIC INITIATIVE
12.20. CLARITAS GENOMICS
12.20.1. OVERVIEW
12.20.2. PRODUCT PORTFOLIO
12.20.3. SCOT ANALYSIS
12.20.4. STRATEGIC INITIATIVE
12.21. ROCHE
12.21.1. OVERVIEW
12.21.2. PRODUCT PORTFOLIO
12.21.3. SCOT ANALYSIS
12.21.4. STRATEGIC INITIATIVE
12.22. LABCORP
12.22.1. OVERVIEW
12.22.2. PRODUCT PORTFOLIO
12.22.3. SCOT ANALYSIS
12.22.4. STRATEGIC INITIATIVE
12.23. AGILENT
12.23.1. OVERVIEW
12.23.2. PRODUCT PORTFOLIO
12.23.3. SCOT ANALYSIS
12.23.4. STRATEGIC INITIATIVE
12.24. INTEGRATED GENETICS
12.24.1. OVERVIEW
12.24.2. PRODUCT PORTFOLIO
12.24.3. SCOT ANALYSIS
12.25. PHOSPHORUS DIAGNOSTICS
12.25.1. OVERVIEW
12.25.2. PRODUCT PORTFOLIO
12.25.3. SCOT ANALYSIS
12.25.4. STRATEGIC INITIATIVE
12.26. CENTOGENE
12.26.1. OVERVIEW
12.26.2. PRODUCT PORTFOLIO
12.26.3. SCOT ANALYSIS
12.26.4. STRATEGIC INITIATIVE
12.27. NATERA INC
12.27.1. OVERVIEW
12.27.2. PRODUCT PORTFOLIO
12.27.3. SCOT ANALYSIS
12.27.4. STRATEGIC INITIATIVE
12.28. ILLUMINA INC
12.28.1. OVERVIEW
12.28.2. PRODUCT PORTFOLIO
12.28.3. SCOT ANALYSIS
12.28.4. STRATEGIC INITIATIVE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE IS THE LARGEST MARKET
3.2.2. ASIA PACIFIC IS THE FASTEST GROWING REGION IN THE INFERTILITY MARKET
3.2.3. IVF DOMINATES THE FEMALE TREATMENT MARKET
3.2.4. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. MARKET DRIVERS AND IMPACT
4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED THE FERTILITY TREATMENT
4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
4.2.6. HEALTHIER DONOR EGGS
4.2.7. INTRODUCTION OF NEW TESTING DEVICES
4.3. RESTRAINTS AND IMPACT
4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED
4.3.2. COUNTRY-WISE REGULATORY ISSUES
4.4. MARKET OPPORTUNITIES
4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
4.5. MARKET CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. PERILS OF MULTIPLE PREGNANCIES
4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO INFERTILITY TREATMENTS
4.5.3.1. DIET AND SUPPLEMENTS
4.5.3.2. ACUPUNCTURE
4.5.3.3. THERAPY
4.5.3.4. QIGONG
5. INFERTILITY CAUSES
5.1. CAUSES OF MALE INFERTILITY
5.1.1. ABNORMALITY IN THE SPERM
5.1.2. ENVIRONMENTAL FACTORS
5.1.3. POOR HEALTH AND LIFESTYLE
5.2. CAUSES OF FEMALE INFERTILITY
5.2.1. OVULATION DISORDERS
5.2.2. DAMAGE TO FALLOPIAN TUBES
5.3. MORAL QUESTIONS
6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
6.1. MARKET BY MALE INFERTILITY TESTING
6.1.1. DNA FRAGMENTATION
6.1.2. OXIDATIVE STRESS ANALYSIS
6.1.3. SPERM PENETRATION ASSAY
6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
6.1.5. SPERM AGGLUTINATION
6.1.6. MICROSCOPIC EXAMINATION
6.1.7. OTHERS
6.2. MARKET BY MALE INFERTILITY TREATMENT
6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)
6.2.2. SPERM RETRIEVAL TREATMENT
6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
6.2.5. VARICOCELE REPAIRS
6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
6.2.7. INTRAUTERINE INSEMINATION (IUI)
6.2.8. IN VITRO FERTILIZATION (IVF)
6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
7.1. MARKET BY FEMALE INFERTILITY TESTING
7.1.1. OVULATION TESTING
7.1.2. HYSTEROSALPINGOGRAPHY
7.1.3. LAPAROSCOPY
7.1.4. TRANSVAGINAL ULTRASOUND
7.1.5. OVARIAN RESERVE TESTING
7.1.6. HORMONAL LEVEL TESTING
7.1.7. OTHERS (GENETIC TESTING)
7.2. MARKET BY FEMALE INFERTILITY TREATMENT
7.2.1. IN VITRO FERTILIZATION
7.2.2. INTRAUTERINE INSEMINATION (IUI)
7.2.3. DRUG AND HORMONE THERAPIES
8. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
8.1. FERTILITY AND SURGICAL CENTERS
8.2. HOSPITALS AND RESEARCH LABORATORIES
8.3. CRYOBANKS
9. KEY ANALYTICS
9.1. PORTER’S 5 FORCE MODEL
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCTS
9.1.3. BARGAINING POWER OF BUYERS
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. VALUE CHAIN ANALYSIS
9.2.1. RAW MATERIAL PROCUREMENT
9.2.2. MANUFACTURING
9.2.3. SUPPLY LOGISTICS
9.2.4. DISTRIBUTION CHANNELS
9.2.5. END USERS
9.3. KEY BUYING CRITERIA
9.3.1. TREATMENT OPTIONS
9.3.2. QUALITY OF MEDICAL PROCEDURES
9.3.3. PRICE OF TREATMENTS
9.3.4. SHIFT TOWARDS MEDICAL TOURISM
9.3.5. REIMBURSEMENT
9.4. REGULATORY FRAMEWORK
9.5. KEY TRENDS
9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
9.5.4. REGULATORY ENVIRONMENT- KEY MARKET ENABLER
9.5.5. MORE COUPLES OPTING FOR SURROGACY
9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
9.6. VENDOR LANDSCAPE
9.7. OPPORTUNITY MATRIX
10. KEY ANALYTICS – TESTING MARKET
10.1. PORTER’S 5 FORCE ANALYSIS
10.1.1. THREAT OF NEW ENTRANTS
10.1.2. THREAT OF SUBSTITUTE PRODUCTS
10.1.3. BARGAINING POWER OF BUYERS
10.1.4. BARGAINING POWER OF SUPPLIERS
10.1.5. INTENSITY OF COMPETITIVE RIVALRY
10.2. KEY BUYING CRITERIA
10.3. VENDOR LANDSCAPE
10.4. OPPORTUNITY MATRIX
11. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET REGIONAL ANALYSIS 2018-2026 ($ MILLION)
11.1. NORTH AMERICA
11.1.1. US
11.1.2. CANADA
11.2. ASIA PACIFIC
11.2.1. CHINA
11.2.2. INDIA
11.2.3. JAPAN
11.2.4. SOUTH KOREA
11.2.5. REST OF ASIA-PACIFIC
11.3. EUROPE
11.3.1. UK
11.3.2. GERMANY
11.3.3. FRANCE
11.3.4. NORDICS
11.3.5. RUSSIA
11.4. REST OF THE WORLD
12. COMPETITIVE ANALYSIS
12.1. ANDROLOGY SOLUTIONS
12.1.1. OVERVIEW
12.1.2. PRODUCT PORTFOLIO
12.1.3. SCOT ANALYSIS
12.2. ENDO PHARMACEUTICALS
12.2.1. OVERVIEW
12.2.2. PRODUCT PORTFOLIO
12.2.3. STRATEGIC MOVES
12.2.4. SCOT ANALYSIS
12.3. PROGYNY
12.3.1. OVERVIEW
12.3.2. PRODUCT PORTFOLIO
12.3.3. STRATEGIC MOVES
12.3.4. SCOT ANALYSIS
12.4. FERRING PHARMACEUTICALS
12.4.1. OVERVIEW
12.4.2. PRODUCT PORTFOLIO
12.4.3. STRATEGIC MOVES
12.4.4. SCOT ANALYSIS
12.5. GENEA
12.5.1. OVERVIEW
12.5.2. PRODUCT PORTFOLIO
12.5.3. STRATEGIC MOVES
12.5.4. SCOT ANALYSIS
12.6. HALOTECH DNA
12.6.1. OVERVIEW
12.6.2. PRODUCT PORTFOLIO
12.6.3. STRATEGIC MOVES
12.6.4. SCOT ANALYSIS
12.7. IRVINE SCIENTIFIC
12.7.1. OVERVIEW
12.7.2. PRODUCT PORTFOLIO
12.7.3. STRATEGIC MOVES
12.7.4. SCOT ANALYSIS
12.8. MERCK
12.8.1. OVERVIEW
12.8.2. PRODUCT PORTFOLIO
12.8.3. STRATEGIC MOVES
12.8.4. SCOT ANALYSIS
12.9. ORIGIO
12.9.1. OVERVIEW
12.9.2. PRODUCT PORTFOLIO
12.9.3. STRATEGIC MOVES
12.9.4. SCOT ANALYSIS
12.10. OVASCIENCE
12.10.1. OVERVIEW
12.10.2. PRODUCT PORTFOLIO
12.10.3. STRATEGIC MOVES
12.10.4. SCOT ANALYSIS
12.11. VITROLIFE AB
12.11.1. OVERVIEW
12.11.2. PRODUCT PORTFOLIO
12.11.3. STRATEGIC MOVES
12.11.4. SCOT ANALYSIS
12.12. THERMO FISHER SCIENTIFIC INC
12.12.1. OVERVIEW
12.12.2. PRODUCT PORTFOLIO
12.12.3. STRATEGIC MOVES
12.12.4. SCOT ANALYSIS
12.13. THE COOPER COMPANIES, INC
12.13.1. OVERVIEW
12.13.2. PRODUCT PORTFOLIO
12.13.3. STRATEGIC MOVES
12.13.4. SCOT ANALYSIS
12.14. QUEST DIAGNOSTIC
12.14.1. OVERVIEW
12.14.2. PRODUCT PORTFOLIO
12.14.3. SCOT ANALYSIS
12.14.4. STRATEGIC MOVES
12.15. ESCO MICRO PTE. LTD.
12.15.1. OVERVIEW
12.15.2. PRODUCT PORTFOLIO
12.15.3. STRATEGIC MOVES
12.15.4. SCOT ANALYSIS
12.16. ELUCIGENE
12.16.1. OVERVIEW
12.16.2. PRODUCT PORTFOLIO
12.16.3. SCOT ANALYSIS
12.16.4. STRATEGIC INITIATIVE
12.17. ALERE
12.17.1. OVERVIEW
12.17.2. PRODUCT PORTFOLIO
12.17.3. SCOT ANALYSIS
12.17.4. STRATEGIC INITIATIVE
12.18. CELMATRIX
12.18.1. OVERVIEW
12.18.2. PRODUCT PORTFOLIO
12.18.3. SCOT ANALYSIS
12.18.4. STRATEGIC INITIATIVE
12.19. VERITAS GENETICS
12.19.1. OVERVIEW
12.19.2. PRODUCT PORTFOLIO
12.19.3. SCOT ANALYSIS
12.19.4. STRATEGIC INITIATIVE
12.20. CLARITAS GENOMICS
12.20.1. OVERVIEW
12.20.2. PRODUCT PORTFOLIO
12.20.3. SCOT ANALYSIS
12.20.4. STRATEGIC INITIATIVE
12.21. ROCHE
12.21.1. OVERVIEW
12.21.2. PRODUCT PORTFOLIO
12.21.3. SCOT ANALYSIS
12.21.4. STRATEGIC INITIATIVE
12.22. LABCORP
12.22.1. OVERVIEW
12.22.2. PRODUCT PORTFOLIO
12.22.3. SCOT ANALYSIS
12.22.4. STRATEGIC INITIATIVE
12.23. AGILENT
12.23.1. OVERVIEW
12.23.2. PRODUCT PORTFOLIO
12.23.3. SCOT ANALYSIS
12.23.4. STRATEGIC INITIATIVE
12.24. INTEGRATED GENETICS
12.24.1. OVERVIEW
12.24.2. PRODUCT PORTFOLIO
12.24.3. SCOT ANALYSIS
12.25. PHOSPHORUS DIAGNOSTICS
12.25.1. OVERVIEW
12.25.2. PRODUCT PORTFOLIO
12.25.3. SCOT ANALYSIS
12.25.4. STRATEGIC INITIATIVE
12.26. CENTOGENE
12.26.1. OVERVIEW
12.26.2. PRODUCT PORTFOLIO
12.26.3. SCOT ANALYSIS
12.26.4. STRATEGIC INITIATIVE
12.27. NATERA INC
12.27.1. OVERVIEW
12.27.2. PRODUCT PORTFOLIO
12.27.3. SCOT ANALYSIS
12.27.4. STRATEGIC INITIATIVE
12.28. ILLUMINA INC
12.28.1. OVERVIEW
12.28.2. PRODUCT PORTFOLIO
12.28.3. SCOT ANALYSIS
12.28.4. STRATEGIC INITIATIVE
LIST OF TABLES
TABLE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 ($ MILLION)
TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
TABLE 3 GLOBAL MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 4 GLOBAL MALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
TABLE 5 PROS AND CONS OF DNA SHARING METHODS
TABLE 6 GLOBAL DNA FRAGMENTATION MARKET BY REGION, 2018-2026 ($MILLION)
TABLE 7 GLOBAL OXIDATIVE STRESS ANALYSIS MARKET BY REGION, 2018-2026 ($MILLION)
TABLE 8 GLOBAL SPERM PENETRATION ASSAY MARKET BY REGION 2018-2026 ($MILLION)
TABLE 9 GLOBAL CASA MARKET BY REGION 2018-2026 ($MILLION)
TABLE 10 GLOBAL SPERM AGGLUTINATION MARKET BY REGION2018-2026 ($MILLION)
TABLE 11 GLOBAL MICROSCOPIC EXAMINATION MARKET BY REGION 2018-2026 ($MILLION)
TABLE 12 GLOBAL FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 13 GLOBAL FEMALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
TABLE 14 COST OF OVULATION TESTING KITS IN THE US
TABLE 15 GLOBAL OVULATION TESTING MARKET BY REGION 2018-2026 ($MILLION)
TABLE 16 GLOBAL HYSTEROSALPINGOGRAPHY MARKET BY REGION 2018-2026 ($MILLION)
TABLE 17 GLOBAL LAPAROSCOPY MARKET BY REGION 2018-2026 ($MILLION)
TABLE 18 GLOBAL TRANSVAGINAL ULTRASOUND MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 19 GLOBAL OVARIAN RESERVE TESTING MARKET BY REGION 2018-2026 ($MILLION)
TABLE 20 GLOBAL HORMONAL LEVEL TESTING MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 21 COST OF HORMONAL TEST IN THE US
TABLE 22 GLOBAL FEMALE INFERTILITY TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 23 AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 24 GLOBAL IVF TREATMENT MARKET BY REGION 2018-2026 ($MILLION)
TABLE 25 GLOBAL IUI TREATMENT MARKET BY REGION 2018-2026 ($MILLION)
TABLE 26 GLOBAL DRUG AND HORMONE THERAPIES MARKET BY REGION 2018-2026 ($MILLION)
TABLE 27 SOME COMMON DRUG THERAPIES
TABLE 28 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
TABLE 29 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 30 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 31 GLOBAL CRYOBANKS MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 32 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 33 NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 34 SUCCESS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) USING DONOR EGGS IN THE U.S. IN 2013
TABLE 35 COSTS FOR INFERTILITY TREATMENTS IN THE U.S. 2015
TABLE 36 COST OF IVF & ICSI TREATMENT, CANADA 2014
TABLE 37 ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
TABLE 38 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
TABLE 39 COST OF IVF IN RUSSIA
TABLE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 ($ MILLION)
TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
TABLE 3 GLOBAL MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 4 GLOBAL MALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
TABLE 5 PROS AND CONS OF DNA SHARING METHODS
TABLE 6 GLOBAL DNA FRAGMENTATION MARKET BY REGION, 2018-2026 ($MILLION)
TABLE 7 GLOBAL OXIDATIVE STRESS ANALYSIS MARKET BY REGION, 2018-2026 ($MILLION)
TABLE 8 GLOBAL SPERM PENETRATION ASSAY MARKET BY REGION 2018-2026 ($MILLION)
TABLE 9 GLOBAL CASA MARKET BY REGION 2018-2026 ($MILLION)
TABLE 10 GLOBAL SPERM AGGLUTINATION MARKET BY REGION2018-2026 ($MILLION)
TABLE 11 GLOBAL MICROSCOPIC EXAMINATION MARKET BY REGION 2018-2026 ($MILLION)
TABLE 12 GLOBAL FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 13 GLOBAL FEMALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
TABLE 14 COST OF OVULATION TESTING KITS IN THE US
TABLE 15 GLOBAL OVULATION TESTING MARKET BY REGION 2018-2026 ($MILLION)
TABLE 16 GLOBAL HYSTEROSALPINGOGRAPHY MARKET BY REGION 2018-2026 ($MILLION)
TABLE 17 GLOBAL LAPAROSCOPY MARKET BY REGION 2018-2026 ($MILLION)
TABLE 18 GLOBAL TRANSVAGINAL ULTRASOUND MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 19 GLOBAL OVARIAN RESERVE TESTING MARKET BY REGION 2018-2026 ($MILLION)
TABLE 20 GLOBAL HORMONAL LEVEL TESTING MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 21 COST OF HORMONAL TEST IN THE US
TABLE 22 GLOBAL FEMALE INFERTILITY TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 23 AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 24 GLOBAL IVF TREATMENT MARKET BY REGION 2018-2026 ($MILLION)
TABLE 25 GLOBAL IUI TREATMENT MARKET BY REGION 2018-2026 ($MILLION)
TABLE 26 GLOBAL DRUG AND HORMONE THERAPIES MARKET BY REGION 2018-2026 ($MILLION)
TABLE 27 SOME COMMON DRUG THERAPIES
TABLE 28 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
TABLE 29 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 30 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 31 GLOBAL CRYOBANKS MARKET BY REGION 2018-2026 ($ MILLION)
TABLE 32 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 33 NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 34 SUCCESS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) USING DONOR EGGS IN THE U.S. IN 2013
TABLE 35 COSTS FOR INFERTILITY TREATMENTS IN THE U.S. 2015
TABLE 36 COST OF IVF & ICSI TREATMENT, CANADA 2014
TABLE 37 ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
TABLE 38 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
TABLE 39 COST OF IVF IN RUSSIA
LIST OF FIGURES
FIGURE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
FIGURE 4 RATE OF MULTIPLE DELIVERIES
FIGURE 5 CAUSES OF INFERTILITY
FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
FIGURE 7CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 8 WORLDWIDE FALLING FERTILITY RATE (TOTAL BIRTHS PER WOMAN)
FIGURE 9 NUMBER OF IVF CYCLES PERFORMED IN THE US
FIGURE 10 US INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 11 CANADA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 12 GROWTH IN IVF CLINICS IN ASIA
FIGURE 13 CHINA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 ($MILLION)
FIGURE 14 INDIA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 ($MILLION)
FIGURE 15 JAPAN INFERTILITY TESTING AND TREATMENT MARKET2018-2026(MILLION)
FIGURE 16 SOUTH KOREA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 (MILLION)
FIGURE 17 MEDICAL TOURISM IN SOUTH KOREA ($ MILLION)
FIGURE 18 REST OF ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
FIGURE 19 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 20 FERTILITY TREATMENT IN 2014
FIGURE 21 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 22 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 23 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 24 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 25 REST OF THE WORLD INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENEA
6. HALOTECH DNA
7. IRVINE SCIENTIFIC
8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC
13. THE COOPER COMPANIES, INC
14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
.27. NATERA INC
28. ILLUMINA INC
FIGURE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
FIGURE 4 RATE OF MULTIPLE DELIVERIES
FIGURE 5 CAUSES OF INFERTILITY
FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
FIGURE 7CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 8 WORLDWIDE FALLING FERTILITY RATE (TOTAL BIRTHS PER WOMAN)
FIGURE 9 NUMBER OF IVF CYCLES PERFORMED IN THE US
FIGURE 10 US INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 11 CANADA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 12 GROWTH IN IVF CLINICS IN ASIA
FIGURE 13 CHINA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 ($MILLION)
FIGURE 14 INDIA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 ($MILLION)
FIGURE 15 JAPAN INFERTILITY TESTING AND TREATMENT MARKET2018-2026(MILLION)
FIGURE 16 SOUTH KOREA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 (MILLION)
FIGURE 17 MEDICAL TOURISM IN SOUTH KOREA ($ MILLION)
FIGURE 18 REST OF ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
FIGURE 19 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 20 FERTILITY TREATMENT IN 2014
FIGURE 21 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 22 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 23 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 24 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 25 REST OF THE WORLD INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENEA
6. HALOTECH DNA
7. IRVINE SCIENTIFIC
8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC
13. THE COOPER COMPANIES, INC
14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
.27. NATERA INC
28. ILLUMINA INC
